Advertisement

Topics

Latest "Epithelial Healing And Visual Outcomes Using Omega-3 Therapy Before And After Photorefractive Keratectomy (PRK) Surgery" News Stories

19:34 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Epithelial Healing And Visual Outcomes Using Omega-3 Therapy Before And After Photorefractive Keratectomy (PRK) Surgery" found in our extensive news archives from over 250 global news sources.

More Information about Epithelial Healing And Visual Outcomes Using Omega-3 Therapy Before And After Photorefractive Keratectomy (PRK) Surgery on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Epithelial Healing And Visual Outcomes Using Omega-3 Therapy Before And After Photorefractive Keratectomy (PRK) Surgery for you to read. Along with our medical data and news we also list Epithelial Healing And Visual Outcomes Using Omega-3 Therapy Before And After Photorefractive Keratectomy (PRK) Surgery Clinical Trials, which are updated daily. BioPortfolio also has a large database of Epithelial Healing And Visual Outcomes Using Omega-3 Therapy Before And After Photorefractive Keratectomy (PRK) Surgery Companies for you to search.

Showing "Epithelial Healing Visual Outcomes Using Omega Therapy Before" News Articles 1–25 of 9,300+

Wednesday 20th March 2019

FDA approves first-ever postpartum #depression therapy: Sage Therapeutics' Zulresso http://bit.ly/2TiUNmr  #postpartumdepression #pharma

FDA approves first-ever postpartum #depression therapy: Sage Therapeutics' Zulresso http://bit.ly/2TiUNmr  #postpartumdepression #pharma


Asia Deal Watch: Zogenix Partners Japanese Rights To Pediatric Epilepsy Therapy To Nippon Shinyaku

Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its...   

CoverMyMeds: Prior authorization scripts get filled faster when submitted electronically


Biofrontera AG: Biofrontera Reports Positive Phase III Results with Ameluz(R) for photodynamic therapy of actinic keratoses on the extremities and trunk/neck

Biofrontera AG / Key word(s): Study results Biofrontera AG: Biofrontera Reports Positive Phase III Results with Ameluz(R) for photodynamic therapy of actinic keratoses on the extremities and trunk/neck 20-March-2019 / 15:50 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is ...

Cancer doctor shortage ‘will impact patients’, says Royal College

News report A shortage of cancer doctors in the NHS is likely to impact patients, according to a new report. The study, from the Royal College of Radiologists (RCR), points to a growing shortage of staff, with 1 in 6 UK cancer centres now operating with fewer cancer doctors, called clinical oncologists

Center for Gene and Cell Therapy Co-founded by Miltenyi and ATLATL in Shanghai

To accelerate the development of cell and gene therapy, ATLATL Center and Miltenyi Biotec have cooperated to build ATLATL-MACS Center for Gene and Cell Therapy. Miltenyi is a global leader in the design, development, manufacturing, and integration of products that empower the advancement of biomedical research and enable cutting-edge cell and gene ...

Treating Parents Effective for Child Anxiety

A novel program that helps parents decrease "family accommodation" is as effective for reducing anxiety in their offspring as cognitive behavioral therapy for the child, new research suggests. Medscape Medical News

Proteintech Announces Travel Grant Winners for AACR Annual Meeting 2019

Proteintech, the benchmark in antibodies, today announced the winners of the 2019 American Association for Cancer Research (AACR) Annual Meeting Travel Grant awards. Uday Pratap of University of Texas Health Science Center at San Antonio and Renzo Perales-Linares of the University of Pennsylvania have each been awarded $1,000 each to cover expenses to atte...

Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic®

Bagsværd, Denmark, 20 March 2019 - Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue in a tablet, as well as a supplemental NDA (sNDA) for once-weekly Ozempic® (semaglutide). An NDA was submitted for oral semaglutide seeking appr...

P-MEC China to Arrive in June as Shanghai Gathers International Advanced Pharmaceutical Equipment

SHANGHAI, March 20, 2019 /PRNewswire/ -- Continued innovation and increased investment will become the theme of Chinese pharmaceutical enterprises' development in 2019 with the continuous advancement of generic drug consistency evaluation, acceleration of review and approval, and implementation of procurement with target quantity. With such a background, improving pharmaceutical machinery and pack...

Pfizer Gains Option to Buy Rare Disease Gene Therapy Developer Vivet for Up to $687M

Pfizer said today it has acquired an exclusive option to acquire Vivet Therapeutics, in an up-to-€605 million ($687 million) deal through which the pharma giant has taken an immediate 15% equity interest in rare disease gene therapy developer. Based in Paris, privately-held Vivet specializes in developing gene therapies for inherited liver disorders with high unmet […] The post Pfizer Gain...

Research Publication Suggests Metadichol® Could Reverse Age Related Diseases.

Aging is a law of nature and unavoidable. Instead of targeting a multitude of diseases that confront us as we age Metadichol is about correcting the root cause of diseases as exemplified by our patents and publications. Source. Nanorx Inc CHAPPAQUA, N.Y. (PRWEB) March 20, 2019 Many companies are developing anti-aging drugs using telomerase activation, but Nanorx Inc is paving the way for safe cli...

Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal

Pfizer this morning added to its methodical push into the gene therapy field, paying $51 million for a 15 percent stake in Vivet Therapeutics and the option to buy the Parisian biotech in the future. Vivet is developing an experimental gene therapy, VTX-801, for the rare genetic disorder Wilson’s disease, which causes a potentially deadly […]

DentalPlans.com Reminds Workers to Protect Their Eyes on The Job

Eye Safety Advice for National Workplace Eye Wellness Month Every day, about 2,000 U.S. workers experience a job-related eye injury, one-third requiring care in an emergency room, and many causing temporary or permanent vision loss. To honor March as Workplace Eye Wellness Month, an initiative aimed to raise awareness about eye protection on the job,

AvoDerm® Natural Pet Foods, Nylabone® and Pets Add Life® Champion the Bond Between People and Pets with 15th Season of Bark at the Park

Central Garden & Pet brands, AvoDerm® Natural Pet Foods and Nylabone® and the APPA’s Pets Add Life® campaign return to the field in 2019 with Bark at the Park. This is the 15th season that Central’s brands have partnered with Major League Baseball® teams to bring these family friendly events to thousands of fans. More than 35,000 dogs and their...

Medina Chiropractor Expands Into A New State Of The Art Multidisciplinary Facility With Provider's Onsite From Chiropractor to Neurosurgeon!

Advanced Spine Joint and Wellness is rapidly expanding into Ohio's only truly muti-disciplined facility. and is now offering in Medina, Ohio Chiropractic's, Sports Medicine, Physical Therapy, Massage Therapy, Non-surgical Spinal Decompression, Robotic Laser Therapy, Weight Loss,and Onsite Orthopedic and Spine Surgeons! Same day appointments, same day imaging and MRI's are available f...

Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer

The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the...   

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race

Biohaven has acquired a priority review voucher from GW Pharma to accelerate the US review of rimegepant, its oral CGRP...    

New Treatments Might Provide Hope To Patients With Rare Genetic Disease That Turns Tissue Into Bone

The genetic disease, fibrodysplasia ossificans, in which the body’s machinery for healing goes awry, growing immovable bone where it doesn’t belong, had been languishing as nothing more than a medical curiosity. But a community of patient advocates rallied, and now there are three medicines in human trials, the most advanced of which could win Food and Drug Administration approval next year. I...

Pfizer makes sure it won't get left out of the gene therapy deal boom

The big pharma now holds an exclusive option to acquire all shares of a privately held gene therapy biotech based in France.

Severe Asthma in Children: Therapeutic Considerations

Which factors should be considered before escalating treatments in children with severe therapy-resistant asthma? Current Opinion in Allergy and Clinical Immunology

Pfizer takes stake in gene therapy company Vivet Therapeutics, gains purchase option https://www.firstwordpharma.com/node/1630565  $PFE

Pfizer takes stake in gene therapy company Vivet Therapeutics, gains purchase option https://www.firstwordpharma.com/node/1630565  $PFE

Oncorus Announces Four Presentations at AACR Annual Meeting 2019

-- Oral presentation to highlight preclinical data supporting company’s lead oncolytic virus therapy clinical candidate, ONCR-177 -- -- Three poster presentations to showcase multiple, proprietary innovations underlying company’s local and systemic oncolytic virus platforms -- Oncorus, Inc., an oncolytic virus therapeutics...

Pfizer gains option to buy liver gene therapy company Vivet


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks